Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study

Documenti analoghi

• First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study
  di: Pefura Yone, Eric Walter, et al.
  Pubblicazione: (2011)
• First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study
  di: Kengne André, et al.
  Pubblicazione: (2011-09-01)
• Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors
  di: Rao, Madhu N., et al.
  Pubblicazione: (2006)
• Use of Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors Among Medicaid Beneficiaries With AIDS
  di: Sambamoorthi, Usha, et al.
  Pubblicazione: (2001)
• Sociodemographic Factors Predict Early Discontinuation of HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors
  di: Asad, Shaheena, et al.
  Pubblicazione: (2008)